ABBOTT LABORATORIES acquired Kos Pharmaceuticals, Inc. for $78.00 per share in cash (approximately $3.7 billion), a transaction completed in December 2006, structured as all cash (tender offer and merger).
Kos Pharmaceuticals, Inc. operates in Pharmaceuticals — cardiometabolic / lipid management, is based in Cranbury, New Jersey, USA. Kos Pharmaceuticals is a specialty pharmaceutical company focused on cardiometabolic and respiratory products, including the Niaspan and Advicor lipid-management franchises.
Adds a complementary portfolio of cardiometabolic and lipid-management products to Abbott's pharmaceutical franchise.
Complementary lipid-management and cardiometabolic franchise; shareholders owning ~53% of shares committed to tender, assuring closing. Integrated into Abbott's pharmaceutical business
Advisory firms were not disclosed for this transaction.